These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs. Marsella R, Ahrens K, Wilkes R, Trujillo A, Dorr M. Vet Dermatol; 2020 Aug; 31(4):284-e69. PubMed ID: 32301565 [Abstract] [Full Text] [Related]
5. Lack of Interference of Oclacitinib with the results of intradermal testing or allergen-specific IgE serology in Dermatophagoides farinae-sensitized beagle dogs. Aleo MM, Messamore J, Nieto BA, Fleck TJ, Humphrey WR, Coscarelli EM, Mahabir SP, McCall RB, Gonzales AJ. Vet Immunol Immunopathol; 2023 Feb; 256():110537. PubMed ID: 36603446 [Abstract] [Full Text] [Related]
6. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Cosgrove SB, Cleaver DM, King VL, Gilmer AR, Daniels AE, Wren JA, Stegemann MR. Vet Dermatol; 2015 Jun; 26(3):171-9, e35. PubMed ID: 25688708 [Abstract] [Full Text] [Related]
7. Pilot evaluation of Enterococcus faecium SF68 as adjunctive therapy for oclacitinib-responsive adult atopic dermatitis in dogs. Yamazaki C, Rosenkrantz W, Griffin C. J Small Anim Pract; 2019 Aug; 60(8):499-506. PubMed ID: 31257599 [Abstract] [Full Text] [Related]
8. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study. Simpson AC, Schissler JR, Rosychuk RAW, Moore AR. Vet Dermatol; 2017 Oct; 28(5):485-e113. PubMed ID: 28513001 [Abstract] [Full Text] [Related]
11. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Gadeyne C, Little P, King VL, Edwards N, Davis K, Stegemann MR. Vet Dermatol; 2014 Dec; 25(6):512-8, e86. PubMed ID: 25109820 [Abstract] [Full Text] [Related]
13. Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats. Ortalda C, Noli C, Colombo S, Borio S. Vet Dermatol; 2015 Aug; 26(4):235-e52. PubMed ID: 25940959 [Abstract] [Full Text] [Related]
16. Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response. Carrasco I, Ferrer L, Puigdemont A. J Feline Med Surg; 2022 Aug; 24(8):787-793. PubMed ID: 34612749 [Abstract] [Full Text] [Related]
17. A randomised, double-blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO-524 in dogs with atopic dermatitis. Nishiyama T, Kusakabe M, Imanishi I, Hisano T, Fukamachi T, Taguchi N, Iyori K, Hsiao YH. Vet Dermatol; 2023 Dec; 34(6):523-531. PubMed ID: 37485602 [Abstract] [Full Text] [Related]